The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -2.65 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -2.24 — no flag raisedOK
- Earnings quality 56/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as Twist Bioscience Corp reports it. History and quarterly detail are in the app.
- NGS tools$208.1M
- Synthetic genes$113.6M
- Antibody discovery$23.5M
- Oligo pools$20.2M
- DNA libraries$11.2M
Leadership changes
From Twist Bioscience Corp's own filings, the day they're filed.
- Robert F. Werner · chief accounting officer · appointmenteff. 2023-05-22
- Trynka Shineman Blake · appointment
- James Thorburn · Chief Financial Officer · departure
Latest filings
- 8-K · Company announcement2026-08-19
- 8-K · Company announcement2026-08-19
- 8-K · Company announcement2026-08-05
- 10-Q · Quarterly report2026-08-03
- 8-K · Company announcement2026-08-03
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Twist Bioscience Corp, every answer cited to the official filings🔒
- The Intelligence Brief — added when Twist Bioscience Corp's brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.